BRAINTREE, Mass., July 27, 2012 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Ellen M. Zane was elected to join the Board of Directors at the Company’s Annual Meeting of Shareholders today.
(Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO)
Ms. Zane was formerly President & CEO of Tufts Medical Center & Floating Hospital for Children in Boston from 2004 until her retirement in 2011 and currently serves as Vice Chairman of the Board of Trustees. In addition to her role as Vice Chairman and previous roles as President and CEO, Ms. Zane has been an Assistant Professor in the Department of Medicine, Division of Clinical Care Research, since 2004 and is an Assistant Professor of Public Health and Community Medicine at The Tufts University School of Medicine. Additionally, she is an Adjunct Assistant Professor of Health Policy and Management at The Harvard School of Public Health.
Prior to joining Tufts Medical Center, Ms. Zane, who has over 30 years of healthcare industry experience, was Network President of Partners Healthcare System from 1994 to 2004. She was Chief Executive Officer and previously Chief Operating Officer of Quincy Hospital from 1987 to 1994 and held a number of senior professional services leadership positions with Morton Hospital & Medical Center from 1979 to 1987 and Lawrence General Hospital from 1975 to 1979.
Ms. Zane currently serves on the Boards of Directors of Brooks Automation, Lincare Holdings Inc., Parexel International Corporation, Century Capital Management, George Washington University, and the Health Policy and Management Council of the Harvard School of Public Health. She has an MA degree from Catholic University of America, a BA degree from George Washington University and honorary doctorate degrees from Bentley University, Stonehill College and Curry College.
Richard J. Meelia, Chairman of Haemonetics’ Board of Directors commented, “Ellen brings extensive functional and leadership experience gained in the delivery of healthcare to our Board of Directors. Her contributions will be helpful in guiding the Company as it seeks to leverage its blood management solutions and continue its recent growth.”
“Blood management is a key focal point of hospital administrators and surgical teams as they seek to provide the best possible clinical care for patients while managing their cost structures. Haemonetics is very well positioned with solutions that are central to those efforts,” said Ms. Zane. “I look forward to joining the Board of Directors and serving the Company’s shareholders.”
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.
CONTACT:
Gerry Gould, VP-Investor Relations
Tel. (781) 356-9402
Alt. (781) 356-9613
gerry.gould@haemonetics.com
SOURCE Haemonetics Corporation
